New therapeutic options for HCV infection in the monoclonal antibody era

Giuseppe Andrea Sautto, Roberta Antonia Diotti, Massimo Clementi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and the most common indication for liver transplantation. Current therapies are ineffective in a relevant percentage of patients raising the urgent medical need to develop adequate therapies for this infection. Broadly neutralizing human monoclonal antibodies (mAbs) directed against the HCV E2 glycoprotein (HCV/E2), the major target of the neutralizing humoral immune response, are considered as a possible novel therapeutic strategy for this infection. In the last few years, several anti-HCV/E2 human mAbs have been described in literature to be possibly used for therapeutic or prophylactic purposes. In this review, we illustrate the best candidates for an anti-HCV mAb-based therapy, considering their cross-neutralization profiles and their ability to overcome possible viral escape mechanisms.

Original languageEnglish
Pages (from-to)387-397
Number of pages11
JournalNew Microbiologica
Volume35
Issue number4
Publication statusPublished - 2012

Fingerprint

Virus Diseases
Hepacivirus
Monoclonal Antibodies
Therapeutics
Humoral Immunity
Infection
Liver Transplantation
Liver Diseases
Chronic Disease

Keywords

  • Anti-HCV/E2 mAbs
  • Hcv
  • MAbs
  • Viral escape

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

New therapeutic options for HCV infection in the monoclonal antibody era. / Sautto, Giuseppe Andrea; Diotti, Roberta Antonia; Clementi, Massimo.

In: New Microbiologica, Vol. 35, No. 4, 2012, p. 387-397.

Research output: Contribution to journalArticle

Sautto, Giuseppe Andrea ; Diotti, Roberta Antonia ; Clementi, Massimo. / New therapeutic options for HCV infection in the monoclonal antibody era. In: New Microbiologica. 2012 ; Vol. 35, No. 4. pp. 387-397.
@article{3ebf112bf7174018b8e83af4c136489a,
title = "New therapeutic options for HCV infection in the monoclonal antibody era",
abstract = "Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and the most common indication for liver transplantation. Current therapies are ineffective in a relevant percentage of patients raising the urgent medical need to develop adequate therapies for this infection. Broadly neutralizing human monoclonal antibodies (mAbs) directed against the HCV E2 glycoprotein (HCV/E2), the major target of the neutralizing humoral immune response, are considered as a possible novel therapeutic strategy for this infection. In the last few years, several anti-HCV/E2 human mAbs have been described in literature to be possibly used for therapeutic or prophylactic purposes. In this review, we illustrate the best candidates for an anti-HCV mAb-based therapy, considering their cross-neutralization profiles and their ability to overcome possible viral escape mechanisms.",
keywords = "Anti-HCV/E2 mAbs, Hcv, MAbs, Viral escape",
author = "Sautto, {Giuseppe Andrea} and Diotti, {Roberta Antonia} and Massimo Clementi",
year = "2012",
language = "English",
volume = "35",
pages = "387--397",
journal = "New Microbiologica",
issn = "1121-7138",
publisher = "Luigi Ponzio e figlio Editori",
number = "4",

}

TY - JOUR

T1 - New therapeutic options for HCV infection in the monoclonal antibody era

AU - Sautto, Giuseppe Andrea

AU - Diotti, Roberta Antonia

AU - Clementi, Massimo

PY - 2012

Y1 - 2012

N2 - Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and the most common indication for liver transplantation. Current therapies are ineffective in a relevant percentage of patients raising the urgent medical need to develop adequate therapies for this infection. Broadly neutralizing human monoclonal antibodies (mAbs) directed against the HCV E2 glycoprotein (HCV/E2), the major target of the neutralizing humoral immune response, are considered as a possible novel therapeutic strategy for this infection. In the last few years, several anti-HCV/E2 human mAbs have been described in literature to be possibly used for therapeutic or prophylactic purposes. In this review, we illustrate the best candidates for an anti-HCV mAb-based therapy, considering their cross-neutralization profiles and their ability to overcome possible viral escape mechanisms.

AB - Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and the most common indication for liver transplantation. Current therapies are ineffective in a relevant percentage of patients raising the urgent medical need to develop adequate therapies for this infection. Broadly neutralizing human monoclonal antibodies (mAbs) directed against the HCV E2 glycoprotein (HCV/E2), the major target of the neutralizing humoral immune response, are considered as a possible novel therapeutic strategy for this infection. In the last few years, several anti-HCV/E2 human mAbs have been described in literature to be possibly used for therapeutic or prophylactic purposes. In this review, we illustrate the best candidates for an anti-HCV mAb-based therapy, considering their cross-neutralization profiles and their ability to overcome possible viral escape mechanisms.

KW - Anti-HCV/E2 mAbs

KW - Hcv

KW - MAbs

KW - Viral escape

UR - http://www.scopus.com/inward/record.url?scp=84869202423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869202423&partnerID=8YFLogxK

M3 - Article

C2 - 23109006

AN - SCOPUS:84869202423

VL - 35

SP - 387

EP - 397

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 4

ER -